Trial Profile

A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects With Metastatic or Unresectable Non-Small Cell Lung Cancer and Other Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 25 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Izalontamab brengitecan (Primary)
Indications Carcinoma; Head and neck cancer; HER2 negative breast cancer; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions
Acronyms US-Lung-101
Sponsors SystImmune

17 Oct 2025 According to SystImmune media release, data from the trial were presented at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany.
17 Oct 2025 Results presented in the SystImmune Media Release
24 Sep 2025 According to SystImmune media release, the data from the trial will be presented at the European Society for Medical Oncology (ESMO) Congress 2025, taking place October 17-21 in Berlin, Germany.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com